A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

PHASE3CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

December 31, 1992

Primary Completion Date

December 31, 1993

Study Completion Date

December 31, 1993

Conditions
Ocular HypertensionOpen Angle Glaucoma
Interventions
DRUG

timolol

One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle

DRUG

PhXA41

One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.

Trial Locations (12)

AB25 2ZD

Pfizer Investigational Site, Aberdeen

NG7 2UH

Pfizer Investigational Site, Nottingham

BS1 2LX

Pfizer Investigational Site, Bristol

Unknown

Pfizer Investigational Site, Cambridge

Pfizer Investigational Site, London

Pfizer Investigational Site, Manchester

Pfizer Investigational Site, Paisley

CF4 4XW

Pfizer Investigational Site, Cardiff

DD2 9SY

Pfizer Investigational Site, Dundee

L7 8XP

Pfizer Investigational Site, Liverpool

NW3 2QG

Pfizer Investigational Site, London

S10 2JF

Pfizer Investigational Site, Sheffield

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00751049 - A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom | Biotech Hunter | Biotech Hunter